IPSOGEN
Ipsogen is develops and markets diagnostic tests in the field of oncology worldwide. The company offers diagnostic kits and biomarkers. Its products are used in the diagnosis, prognosis, and monitoring of patients with leukemia.
IPSOGEN
Industry:
Biotechnology Health Care Health Diagnostics Life Science
Founded:
1999-01-01
Address:
Marseille, Provence-Alpes-Cote D'Azur, France
Country:
France
Total Employee:
51+
Status:
Active
Contact:
+33 4 91 29 30 90
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Font Awesome ReCAPTCHA COVID-19 Vimeo MediaElement.js Varnish Adobe Dynamic Tag Management Disqus
Similar Organizations
CardioGenics
CardioGenics develops sensitive diagnostic test products to the IVD market.
Cytofind Diagnostics
Cytofind Diagnostics develops unique technology in the field of oncology diagnostics to improve outcomes & quality of life.
g-Nostics
G-Nostics develops diagnostic treatments and tests for individuals undergoing drug rehabilitation.
HepQuant
HepQuant develops minimally invasive diagnostics for liver function.
Immumed GmbH
Immumed GmbH operates as a development and service company for medical diagnostic problems in the field of immunology.
Investors List
Octalfa
Octalfa investment in Venture Round - Ipsogen
More informations about "Ipsogen"
Ipsogen - Crunchbase Company Profile & Funding
Organization. Ipsogen . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Ipsogen is develops and markets diagnostic tests …See details»
Ipsogen: Personalized Medicine: Vol 5 , No 1 - Get Access
Dec 26, 2007 Ipsogen was founded in 1999, ... The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial …See details»
Ipsogen Company Profile 2024: Valuation, Investors, Acquisition
Ipsogen General Information Description. Provider of molecular testing services. The company develops and markets innovative molecular diagnostic tools to clinical centers and hospitals …See details»
QIAGEN to acquire Ipsogen - News-Medical.net
Jun 15, 2011 QIAGEN N.V. has made an offer and entered into exclusive negotiations to purchase a 47% initial stake in Ipsogen S.A. and subsequently make a public offer to fully …See details»
Ipsogen - Funding, Financials, Valuation & Investors - Crunchbase
Ipsogen is develops and markets diagnostic tests in the field of oncology worldwide. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. ... How …See details»
QIAGEN Makes Proposal to Fully Acquire Ipsogen
Jun 15, 2011 "The acquisition of Ipsogen would further expand our global leadership in molecular assays for profiling and personalized healthcare," said Peer Schatz, Chief Executive …See details»
Ipsogen - PubMed
Ipsogen is a molecular diagnostics company focused on the development and commercialization of innovative tests used to guide and personalize treatment options in cancer. Ipsogen has …See details»
QIAGEN - Sample to Insight
Ipsogen — a complete range of oncohematology assays. ipsogen kits provide: Sensitive and precise qualitative and quantitative assays ; Standardized assays for reproducible results ; …See details»
Ipsogen - Crunchbase
Ipsogen is develops and markets diagnostic tests in the field of oncology worldwide.See details»
Ipsogen | Personalized Medicine
Ipsogen is a molecular diagnostics company focused on the development and commercialization of innovative tests used to guide and personalize treatment options in cancer. Ipsogen has …See details»
Q&A with QIAGEN about Ipsogen buy - Fierce Biotech
Jun 29, 2011 Recently, QIAGEN announced it has entered into talks to purchase a 47 percent initial stake in France's Ipsogen and subsequently make a public offer to fully acquire the …See details»
Ipsogen - ResearchGate
Jan 1, 2008 Ipsogen is a molecular diagnostics company focused on the development and commercialization of innovative tests used to guide and personalize treatment options on cancer.See details»
Ipsogen Genetics & Genomics News - GenomeWeb
Qiagen's planned acquisition of Ipsogen will provide the firm with a suite of CE-IVD marked PCR tests as well as an Affymetrix-manufactured microarray test that can be used to guide …See details»
QIAGEN receives FDA clearance for first-ever JAK2 test for use in ...
Jan 23, 2018 *The ipsogen JAK2 RGQ PCR Kit is a qualitative in vitro diagnostic test for the detection of the JAK2 V617F/G1849T allele in genomic DNA extracted from EDTA whole …See details»
Ipsogen and AstraZeneca Partner for Cancer Study
Dec 13, 2007 Ipsogen is the exclusive worldwide licensee of the intellectual property on JAK2 V617F mutation discovered by a team from Inserm, France. Inserm is a public organization …See details»
iProgen
Ken is a biotech entrepreneur with 25 years of experience in the field. Ken’s journey has seen him navigate through target discovery at the BC Cancer Research Center, preclinical research at …See details»
Home | QIAGEN Oncohematology Research - hemoncbyqiagen.com
Oncohematology Research with ipsogen Major advancements in hematological cancer research were made by the discovery of disease-specific molecular markers. Take those advancements …See details»
ipsogen Standards - QIAGEN
Ipsogen Standards precisely quantify the copy number of control gene, fusion gene, or mutated gene transcripts by generating standard curves based on the known concentration of plasmid …See details»
QIAGEN Receives FDA Clearance for JAK2 Diagnostic Test
Jan 24, 2018 The analysis of JAK2 is a major criterion for the diagnosis of all MPNs in the WHO (World Health Organization) 2016 guidelines for the classification of MPNs. ... * The ipsogen …See details»
ipsogen RT Kit - QIAGEN
The ipsogen RT Kit is a ready-to-use kit for reverse transcription of total RNA into cDNA using reverse transcription-PCR (RT-PCR). The kit provides accurate and reproducible reverse …See details»